The US Food and Drug Administration replaced its medical-device cybersecurity guidance in February 2026, updating recommendations tied to statutory duties that took effect in 2023. Taiwan's regulator publishes a 2021 lifecycle guide and five reference templates, but the cited public material does not establish a US-style statutory submission rule.
Shionogi launched ENDEAVORRIDE in Japan on June 5, 2026 after Japanese regulators reviewed local and US clinical data. The company also holds Taiwan rights, but APPI News could not verify a Taiwan license or public filing.
VA Providence began rolling out an ambient AI scribe in primary care on March 24, 2026, with participation optional for veterans. The software turns clinical conversations into draft notes, leaving accuracy, consent and liability subject to rules that vary by country.
The 2019 Apple Heart Study sent irregular-pulse notifications to 0.52 percent of 419,297 participants, while later ECG patches found atrial fibrillation in 34 percent of 450 analyzable recipients. Its 84 percent positive predictive value measured a different event: another alert that occurred during simultaneous ECG recording.
National Taiwan University Hospital said in 2026 that it had built a federated-learning platform with partner hospitals to validate medical AI without moving their data off site. The approach limits centralized data collection, but it does not eliminate privacy, performance or accountability risks.
The US Food and Drug Administration cleared AEYE-DS for use with the handheld Optomed Aurora retinal camera on April 23, 2024. The system automatically returns a screening result, but its authorization and performance data have defined limits.
The US Food and Drug Administration announced its first TEMPO participant on July 22, 2026 and now lists two manufacturers in the pilot. Their devices can enter Medicare-supported care through conditional enforcement discretion and real-world data collection, not a finding of effectiveness for the uses under review.
UC San Diego researchers reported on July 8, 2026, that a surgeon remotely controlled a humanoid robot during two gallbladder operations on pigs. The study showed technical feasibility, but human bedside assistance, repeated recalibration and sterility problems remain barriers to clinical use.
Taiwan added 17 smart assistive products to a long-term-care rental benefit on July 1, 2026. The published list identifies products and suppliers but does not provide performance metrics or explain how each system makes decisions.
OpenAI began rolling out Health in ChatGPT to US adults on July 23, 2026, with connections to Apple Health and supported medical records. Taiwan's My Health Bank SDK instead sends selected records to third-party apps after a government review, and new SDK applications are currently paused.
Researchers in South Korea and the United States reported two manufacturing advances for stretchable electronics in 2026. One kept liquid-metal conductors working under repeated strain, while the other put a dense computing array on a stretchable patch, but neither study tested a finished implant in people.
A systematic review published in January 2026 found that generative AI increased the volume, speed and perceived credibility of health misinformation in the available studies. Clinicians can use the same tools to draft public information, but the evidence and professional guidance leave accuracy, privacy and disclosure with the person who publishes it.
A July 30, 2026 Coldcard advisory showed how a random-number integration error could remain hidden while security-sensitive outputs still looked valid. The same failure pattern matters in health information systems that generate pseudonyms and SMART on FHIR authorization secrets.
A September 2025 paper argued that language-model training and widely used benchmarks reward guessing over acknowledging uncertainty. A 2026 health-chatbot audit found 49.6 percent of answers problematic, showing how fluent errors can reach high-stakes uses.
Rwanda is expanding a medical drone network that has carried blood and other supplies since 2016. Faster deliveries can reduce delays and waste, but reporting from rural facilities shows that aircraft cannot supply missing staff, equipment or continuing care.
Taiwan-listed Bionime secured a local medical-device license for its iFree2 continuous glucose monitor in April 2026, but the public notice did not identify an AI forecasting feature. Abbott's Libre Assist offers such predictions in the United States, while Abbott's Taiwan product site lists an older sensor and does not advertise the feature.
A 2025 laboratory study found that six wrist-worn trackers identified more than 90 percent of sleep intervals but correctly identified only 29.39 percent to 52.15 percent of wake intervals. Their movement and pulse sensors can show broad patterns, but their sleep-stage estimates do not match direct physiological measurements consistently.
A 2026 Hong Kong cohort study found that speech-response EEG data collected in infancy could help forecast language delay through 32 months of age. The model retained an area under the curve above 0.90 in an independent test set, but it has not been validated across languages or presented as a stand-alone diagnosis.
Oregon enacted an AI companion law in 2026 that requires crisis protocols and allows harmed users to sue. Illinois, Nebraska, Tennessee and Maine have taken different approaches, leaving the rules dependent on a product's claims, design and users.
Taiwan's health ministry says three hospital groups completed a cross-system FHIR demonstration by the end of 2025. The standard can make records easier for software and AI tools to query, but it does not settle data quality, access control or accountability.
The World Health Organization and the International Telecommunication Union mapped the use of AI in traditional medicine in a 2025 technical brief. Their findings, combined with international medical-software standards, show why a product demonstration cannot establish clinical credibility.
A 2024 systematic review found that explainable AI increased clinicians' trust in five of 10 empirical studies, while two reported mixed effects. A COVID-19 drug-repurposing project shows how an inspectable workflow can support expert review, but explanations do not establish clinical validity.
A coalition of US state attorneys general reportedly opened an investigation into OpenAI on June 12, 2026, seeking records on advertising, data practices and vulnerable users. The subpoena arrived four days after OpenAI disclosed a confidential draft S-1, but neither the filing nor the subpoena is public.
International guidance gives health organizations a practical set of controls to test before deploying generative AI. The work starts with data handling and audit design, then extends to source traceability, human authority and continuous monitoring.
Taiwan Health Nexus began operations on January 9, 2026, with plans to connect health records held by separate institutions for AI and research. Its public claims address interoperability, but evidence on consent, oversight and commercial reuse remains limited.
Taiwan launched TwHealth Nexus on January 9, 2026, with plans to connect health records held by hospitals and other care providers. The project goes beyond Taiwan's patient-facing My Health Bank service by proposing secondary data use for research and AI, raising separate questions about consent, withdrawal and oversight.
US regulators updated two software policies in January 2026, clarifying when low-risk wellness products and some clinical decision-support functions fall outside full device oversight. Taiwan requires qualifying AI medical software to enter its device-registration system, while the European Union layers high-risk AI obligations onto existing product rules.
